Evidence map›Paper›PMID 28693183›Full record

ArticleOncology letters2017

High expression of P21-activated kinase 5 protein is associated with poor survival in gastric cancer.

Tomoki Aburatani, Mikito Inokuchi, Yoko Takagi, Toshiaki Ishikawa, Keisuke Okuno, Kentaro Gokita, Chiharu Tomii, Toshiro Tanioka, Hideaki Murase, Sho Otsuki and 3 more

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Tomoki AburataniDepartment of Gastrointestinal Surgery, Tokyo Medical and Dental University, Tokyo 113-8519, Japan.
Mikito InokuchiDepartment of Gastrointestinal Surgery, Tokyo Medical and Dental University, Tokyo 113-8519, Japan.
Yoko TakagiDepartment of Surgical Specialty, Tokyo Medical and Dental University, Tokyo 113-8519, Japan.
Toshiaki IshikawaDepartment of Surgical Specialty, Tokyo Medical and Dental University, Tokyo 113-8519, Japan.
Keisuke OkunoDepartment of Gastrointestinal Surgery, Tokyo Medical and Dental University, Tokyo 113-8519, Japan.
Kentaro GokitaDepartment of Gastrointestinal Surgery, Tokyo Medical and Dental University, Tokyo 113-8519, Japan.
Chiharu TomiiDepartment of Gastrointestinal Surgery, Tokyo Medical and Dental University, Tokyo 113-8519, Japan.
Toshiro TaniokaDepartment of Gastrointestinal Surgery, Tokyo Medical and Dental University, Tokyo 113-8519, Japan.
Hideaki MuraseDepartment of Gastrointestinal Surgery, Tokyo Medical and Dental University, Tokyo 113-8519, Japan.
Sho OtsukiDepartment of Gastrointestinal Surgery, Tokyo Medical and Dental University, Tokyo 113-8519, Japan.
Hiroyuki UetakeDepartment of Surgical Specialty, Tokyo Medical and Dental University, Tokyo 113-8519, Japan.
Kazuyuki KojimaDepartment of Gastrointestinal Surgery, Tokyo Medical and Dental University, Tokyo 113-8519, Japan.
Tatsuyuki KawanoDepartment of Gastrointestinal Surgery, Tokyo Medical and Dental University, Tokyo 113-8519, Japan.
Tokyo Medical and Dental University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

P21-activated kinase 5 (PAK5), also termed PAK7, is one of the six members of the PAK family of serine/threonine kinases, which are downstream effectors in several cancer signaling pathways. PAK5 promotes neural outgrowth, contributes to microtubule stability and induces resistance to apoptosis. However, the clinical importance of PAK5 in gastric cancer has not been comprehensively investigated. In the present study, PAK5 expression was evaluated in gastric cancer tissue samples. Furthermore, the associations between high expression of PAK5, and clinicopathological features and prognosis were examined. PAK5 expression in primary gastric cancer specimens resected from 279 patients who underwent gastrectomy at the Tokyo Medical and Dental University Hospital was evaluated using immunohistochemistry. Of the 279 patients, 44 (15.8%) exhibited high PAK5 expression, which was significantly associated with the differentiated pathological type (differentiated vs. undifferentiated; P<0.001), depth of tumor invasion (T1 vs. T2-T4; P<0.001), lymph node metastasis (N0 vs. N1-N3; P<0.001), presence of distant metastasis or recurrence (present vs. absent; P=0.038), advanced tumor stage (I vs. II-IV; P=0.001) and worse disease-specific survival (P=0.013). In stage I-III disease, 38/254 (15.0%) patients exhibited high PAK5 expression, and high expression of PAK5 was significantly associated with relapse-free interval (P=0.044). PAK5 may serve an important role in tumor progression and influence the outcome of patients with gastric cancer.

Indexed as

gastric cancerimmunohistochemistryP21-activated kinase 5P21-activated kinase 7prognosis

Identifiers

PMID28693183
PMCPMC5494881
OpenAlexW2610548862

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.